Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;11(12):1405-13.
doi: 10.1586/erv.12.126.

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

Shibo Jiang  1 , Maria Elena Bottazzi, Lanying Du, Sara Lustigman, Chien-Te Kent Tseng, Elena Curti, Kathryn Jones, Bin Zhan, Peter J Hotez
Affiliations

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

Shibo Jiang et al. Expert Rev Vaccines. 2012 Dec.

Abstract

A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Partnership for the development of a recombinant receptor-binding domain spike protein-based severe acute respiratory syndrome coronavirus vaccine.
The roles of the major partner institutions are described in the text. cGMP: Current good manufacturing practice.
See this image and copyright information in PMC

References

    1. Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS‑CoV – a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7(3), 226–236 (2009). - PMC - PubMed

    2. •• Excellent review of the role of the spike protein in vaccine development.

    1. Roper RL, Rehm KE. SARS vaccines: where are we? Expert Rev. Vaccines 8(7), 887–898 (2009). - PMC - PubMed
    1. Jaume M, Yip MS, Kam YW et al. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med. J. 18(Suppl. 2), 31–36 (2012). - PubMed
    1. Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279(5), 3197–3201 (2004). - PMC - PubMed

    2. • First description of the receptor-binding domain and its target receptor.

    1. Du L, Zhao G, Li L et al. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem. Biophys. Res. Commun. 384(4), 486–490 (2009). - PMC - PubMed

Websites

    1. Biodefence category A, B, C pathogens. www.niaid.nih.gov/topics/biodefenserelated/biodefense/pages/cata.aspx (Accessed 13 May 2012)
    1. CFR – Code of Federal Regulations Title 21. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=3... (Accessed 27 May 2012)

Publication types

MeSH terms